Renal & Urinary

Pyelonephritis: outpatient vs inpatient management

Clinical Overview and When to Suspect Pyelonephritis

— ~250,000 US cases/year; ~80% outpatient, ~20% require hospitalization

— E. coli causes 75–90%; remainder: Klebsiella, Proteus, Enterobacter, Pseudomonas (catheter/instrumentation), Staphylococcus saprophyticus (young women), Enterococcus (elderly, structural disease)

— Rising fluoroquinolone resistance (>10% in many US regions) and ESBL-producing organisms shift empiric choices

— Classic triad: fever + flank pain (CVA tenderness) + pyuria ± dysuria/frequency

— Atypical presentations in elderly (delirium, vague abdominal pain), diabetics (DKA precipitant), pregnant patients (preterm labor, sepsis), immunosuppressed (minimal localizing signs)

— Any febrile UTI in men, pregnant women, children, or those with structural abnormalities should be treated as complicated pyelonephritis

— Female sex, sexual activity, spermicide use, prior UTI

— Pregnancy (physiologic hydronephrosis, progesterone-mediated ureteral dilation)

— Diabetes mellitus, immunosuppression

— Urinary obstruction (stones, BPH, strictures), neurogenic bladder, indwelling catheters

— Vesicoureteral reflux (especially pediatric)

Board pearl: A febrile UTI in a male patient is pyelonephritis or prostatitis until proven otherwise — never treat as simple cystitis, and always extend antibiotic duration accordingly.

Definition: Pyelonephritis is infection of the renal parenchyma and collecting system, typically ascending from the lower urinary tract. Distinguished from cystitis by systemic features (fever, flank pain, nausea) and from urosepsis by hemodynamic stability.

Epidemiology and microbiology:

When to suspect on Step 3:

Risk factors:

The central Step 3 question: Once diagnosed, outpatient oral therapy vs admission for IV antibiotics? This decision hinges on hemodynamics, ability to tolerate PO, pregnancy, comorbidities, social factors, and resistance patterns.

Presentation Patterns and Key History

— Fever >38°C, chills, rigors — systemic inflammatory response

— Flank or back pain, often unilateral, radiating to groin if associated stone

— Nausea, vomiting — limits PO tolerance, a key triage variable

— Lower tract symptoms (dysuria, frequency, urgency, suprapubic pain) in ~⅔ of cases — absence does NOT rule out pyelonephritis

— Gross hematuria in 30–40%

— Duration of symptoms: >7 days or recent failed outpatient therapy suggests complicated disease or resistant organism

— Recent antibiotics (prior 90 days): predicts resistance — avoid same class empirically

— Recent hospitalization, catheterization, instrumentation: healthcare-associated organisms (Pseudomonas, ESBL, enterococci)

— Stone history or known structural abnormality: mandates imaging

— Pregnancy status and gestational age: automatic admission consideration

— Diabetes, immunosuppression, transplant, HIV: lowers threshold for admission and broadens differential (emphysematous pyelonephritis, fungal)

— Sexual history, spermicide use, new partner

— Travel history: resistant organisms from endemic regions

— Persistent vomiting → can't tolerate PO

— Symptoms >72 hours without improvement on outpatient antibiotics

— Severe pain requiring parenteral analgesia

— Confusion, lightheadedness, syncope → sepsis

— Anuria or decreased urine output → obstruction

— Single kidney, transplant, or known anatomic anomaly

— Young children: fever may be only sign; always obtain catheterized urine

— Elderly: delirium, falls, generalized weakness may dominate; classic triad often absent

Step 3 management: When a patient calls after starting outpatient ciprofloxacin for pyelonephritis and reports persistent fever at 48–72 hours, the next step is in-person evaluation with repeat urine culture and renal imaging (CT or US) to evaluate for abscess or obstruction — not simply switching antibiotics empirically.

Classic symptom cluster (24–48 hour onset):

History elements that change management:

Red-flag history triggering admission consideration:

Pediatric and geriatric framing:

Physical Exam Findings and Hemodynamic Assessment

— Temperature: often >38.5°C; hypothermia <36°C is an ominous sepsis marker

— Heart rate >90, RR >20, SBP <90 or MAP <65: SIRS/sepsis criteria

— qSOFA ≥2 (altered mentation, SBP ≤100, RR ≥22): high mortality risk, escalate

— Orthostatic vitals reveal volume depletion from vomiting/sepsis

— CVA tenderness (Murphy's punch sign): hallmark finding, usually unilateral

— Abdominal exam: suprapubic tenderness, no peritoneal signs (peritonitis suggests alternate diagnosis)

— Pelvic exam in women if STI or PID suspected

— Prostate exam in men with febrile UTI — gentle; avoid vigorous massage in suspected acute prostatitis (bacteremia risk)

— Skin: look for ecthyma gangrenosum (Pseudomonas sepsis), petechiae

— Mental status: confusion in elderly is a sepsis marker, not "baseline UTI delirium"

— Stable, well-appearing, tolerating PO, normal mentation → outpatient candidate

— Tachycardia persisting after antipyretic + IV fluid bolus, hypotension, altered mentation → admit, treat as sepsis with 30 mL/kg crystalloid within 3 hours, lactate, blood cultures, broad-spectrum antibiotics within 1 hour

— Anuria or palpable bladder → obstruction; needs decompression

— Fetal heart tones, uterine tenderness, contractions (preterm labor risk)

— Right-sided flank pain more common due to dextrorotation of gravid uterus

— Crepitus over flank → emphysematous pyelonephritis (gas-forming, diabetic)

— Palpable flank mass → perinephric abscess or hydronephrosis

— Jaundice → consider hepatobiliary differential

CCS pearl: In CCS, the first orders for a febrile flank-pain patient should be vital signs, IV access × 2, urinalysis, urine culture, blood cultures × 2, CBC, BMP, lactate, then move the clock forward 30 minutes before starting antibiotics — but never delay antibiotics beyond 1 hour if septic.

Vital signs are the triage backbone:

Targeted exam:

Hemodynamic assessment dictates disposition:

Pregnancy-specific exam:

Exam findings suggesting complication:

Diagnostic Workup — Initial Labs and Urinalysis

— Pyuria (>10 WBC/hpf or positive leukocyte esterase): sensitive but not specific

— Nitrites: specific for Enterobacteriaceae (E. coli, Klebsiella, Proteus); negative does NOT rule out infection (Enterococcus, Staph saprophyticus, Pseudomonas are nitrite-negative)

— WBC casts: pathognomonic for upper tract involvement

— Hematuria: common; gross hematuria warrants follow-up imaging after resolution

— Bacteriuria on microscopy supports diagnosis

— Obtain before first antibiotic dose

— ≥10⁵ CFU/mL is classic; ≥10⁴ CFU/mL with symptoms is diagnostic

— Catheterized specimen in patients unable to give clean catch, all pregnant patients with ambiguous samples, all children, all suspected catheter-associated UTI

— Susceptibility data guide step-down therapy

— Indicated if admitted, septic, immunocompromised, diabetic, pregnant, or diagnosis uncertain

— Positive in ~20–30% of inpatient pyelonephritis

— Not required for well-appearing outpatients

— CBC: leukocytosis with left shift; leukopenia is a sepsis red flag

— BMP: assess creatinine (AKI from sepsis, obstruction, or contrast risk), electrolytes, glucose (DKA in diabetics)

— Lactate: ≥2 mmol/L suggests tissue hypoperfusion; ≥4 mandates aggressive resuscitation

— CRP/procalcitonin: not required but support bacterial etiology

— Pregnancy test in all reproductive-age women — changes everything

— LFTs if jaundiced or to exclude hepatobiliary mimics

— Bedside bladder scan if retention suspected

— POCUS to assess for hydronephrosis at bedside

Key distinction: Asymptomatic bacteriuria is NOT pyelonephritis and should not be treated except in pregnancy and pre-urologic procedures with anticipated mucosal bleeding — treating it elsewhere drives resistance and C. difficile.

Urinalysis (first and most critical test):

Urine culture (mandatory in pyelonephritis, unlike uncomplicated cystitis):

Blood cultures × 2:

Basic labs:

Point-of-care additions:

Diagnostic Workup — Imaging and Confirmatory Studies

— Failure to improve after 48–72 hours of appropriate antibiotics

— Suspected obstruction (anuria, severe pain, known stones)

— Sepsis or critical illness

— Diabetes, immunocompromise, transplant kidney

— Recurrent pyelonephritis or same-side recurrence

— Hematuria persisting after treatment

— Men with first febrile UTI (evaluate for anatomic cause)

— Pediatric patients per AAP guidelines

— CT abdomen/pelvis with IV contrast: gold standard for adults — detects abscess, emphysematous pyelonephritis, obstruction, perinephric extension, alternate diagnoses

— Non-contrast CT: preferred for suspected stone (allows protocol stone evaluation)

— Renal ultrasound: first-line in pregnancy, children, and renal impairment (no contrast, no radiation); detects hydronephrosis and large abscesses but misses smaller lesions

— MRI: alternative in pregnancy when US inconclusive

— DMSA scan: detects renal scarring in chronic/recurrent pediatric pyelonephritis

— Wedge-shaped areas of hypoenhancement on CT — focal pyelonephritis

— Perinephric fat stranding

— Renal/perinephric abscess: rim-enhancing fluid collection — drainage if >5 cm or not improving

— Emphysematous pyelonephritis: gas within parenchyma — diabetic emergency, urology consult, often nephrectomy

— Hydronephrosis with stone → emergent decompression

— Cystoscopy and VCUG generally NOT in acute setting; reserved for recurrent disease workup

— Post-treatment urine culture not routinely needed except in pregnancy

Board pearl: A diabetic with pyelonephritis not improving at 72 hours → get CT to rule out emphysematous pyelonephritis or perinephric abscess — mortality of untreated emphysematous pyelo approaches 50%, and management requires emergent urology consultation plus possible percutaneous drainage or nephrectomy.

Who needs imaging? Not everyone. Routine uncomplicated pyelonephritis in young, healthy women does NOT require imaging on initial presentation.

Indications for imaging:

Modality selection:

Key imaging findings:

Specialized:

Risk Stratification: Outpatient vs Inpatient Decision

— Hemodynamically stable, no SIRS/sepsis

— Tolerating oral intake (no intractable vomiting)

— Mild-to-moderate symptoms

— No pregnancy

— No significant comorbidity decompensation (DKA, uncontrolled HF, etc.)

— Reliable follow-up within 48–72 hours

— Adequate social support, access to medications, ability to return if worse

— Low likelihood of resistant organism (no recent broad antibiotics, no MDR colonization)

— Normal or near-normal renal function

— Sepsis or septic shock — ICU if vasopressors or lactate ≥4

— Pregnancy (traditionally all admitted; outpatient now considered in select stable second-trimester patients at experienced centers, but default Step 3 answer is admit)

— Inability to tolerate PO (vomiting)

— Hemodynamic instability or persistent tachycardia after fluids

— Obstruction requiring decompression

— Suspected complication: abscess, emphysematous pyelo

— Immunocompromise, transplant, neutropenia

— Significant comorbidity (advanced CKD, cirrhosis, poorly controlled diabetes with DKA)

— Failed outpatient therapy at 48–72 hours

— Concern for adherence or unreliable follow-up

— Men with concern for complicating prostatic source

— Stable patients who need IV antibiotics and fluids but may be dischargeable after 6–24 hours of observation

— Useful for patients who improve rapidly and can transition to oral therapy

Step 3 management: A stable, non-pregnant, well-appearing woman with pyelonephritis who tolerates a test dose of fluids and oral antibiotics in the ED, with 48-hour follow-up arranged, can be discharged on oral fluoroquinolone (if local resistance <10%) or oral TMP-SMX guided by susceptibilities after a single IV/IM long-acting dose of ceftriaxone or an aminoglycoside.

The core Step 3 decision tree. Pyelonephritis exists on a severity spectrum; appropriate triage is the highest-yield exam point.

Outpatient candidates (all must be true):

Mandatory inpatient admission:

Emergency department observation pathway:

Disposition documentation: Always document why outpatient is safe (vitals, PO tolerance, follow-up plan) — medicolegal and Step 3 patient safety point.

Pharmacotherapy — Antibiotic Selection

— Ciprofloxacin 500 mg PO BID × 7 days OR levofloxacin 750 mg daily × 5 days — first-line if local E. coli fluoroquinolone resistance <10%

— If FQ resistance >10% or recent FQ use: give single IV/IM dose of ceftriaxone 1 g, ertapenem 1 g, or gentamicin 5 mg/kg while awaiting susceptibilities, then oral step-down

— TMP-SMX DS BID × 14 days — only if susceptibility confirmed (high empiric resistance)

— Oral beta-lactams (cefpodoxime, cefdinir, amoxicillin-clavulanate) × 10–14 days — less effective than FQ; use only when others contraindicated

— Nitrofurantoin and fosfomycin: NOT for pyelonephritis — inadequate tissue levels

— Ceftriaxone 1 g IV q24h — workhorse for non-severe inpatient pyelonephritis

— Piperacillin-tazobactam 3.375 g IV q6h — sepsis, healthcare exposure, prior resistant organisms

— Cefepime 2 g IV q8h — Pseudomonas coverage, healthcare-associated

— Carbapenem (meropenem, ertapenem): ESBL risk, prior ESBL, severe sepsis with broad exposure history

— Add vancomycin if enterococcal/MRSA suspicion (catheter, prior colonization)

— Aminoglycoside (gentamicin) as adjunct in severe sepsis; monitor renal function

— Switch IV → PO when afebrile 24–48 h, hemodynamically stable, tolerating PO, with susceptibility data

— Total duration: 5–7 days fluoroquinolone, 10–14 days beta-lactam/TMP-SMX, 14 days complicated/men

— IV fluids for volume resuscitation

— Antipyretics (acetaminophen)

— Antiemetics (ondansetron)

— Analgesia (acetaminophen, opioids if severe; avoid NSAIDs in AKI)

Board pearl: Always review the culture at 48–72 hours and tailor therapy — leaving a patient on empiric broad-spectrum when narrow coverage is documented is both a stewardship failure and a high-yield Step 3 wrong-answer pattern.

Empiric outpatient oral regimens:

Empiric inpatient IV regimens:

De-escalation and duration:

Adjunctive therapy:

Procedures and Source Control

— Obstructing stone or stricture with infection — urologic emergency, requires decompression within hours

— Hydronephrosis with sepsis

— Renal or perinephric abscess >5 cm or not responding to antibiotics

— Emphysematous pyelonephritis

— Pyonephrosis (infected, obstructed system)

— Percutaneous nephrostomy tube — preferred in septic patients; performed by interventional radiology under local; rapid, lower physiologic stress

— Retrograde ureteral stent — placed cystoscopically by urology; appropriate in stable patients or when nephrostomy contraindicated

— Definitive stone treatment (ESWL, ureteroscopy, PCNL) is delayed until infection clears — never lithotripsy on an actively infected stone

— <3 cm: typically antibiotics alone, repeat imaging in 1–2 weeks

— 3–5 cm: antibiotics ± percutaneous drainage based on response

— >5 cm or persistent fever despite antibiotics: percutaneous drainage

— Multiloculated or failed drainage: open or laparoscopic drainage

— Class 1 (gas in collecting system only): antibiotics + drainage if obstructed

— Class 2–3: percutaneous drainage + antibiotics

— Class 4 (bilateral or single kidney with extensive gas, or failed drainage): nephrectomy; mortality remains 20–40%

— Foley catheter placement for urinary retention or strict I/O monitoring

— Avoid instrumentation in active infection unless necessary

— Suprapubic catheter if urethral access compromised

CCS pearl: In a septic patient with hydronephrosis and obstructing ureteral stone on CT, the correct CCS sequence is IV fluids → blood cultures → broad-spectrum antibiotics → urgent urology consult for percutaneous nephrostomy or stent → ICU admission — definitive stone removal is deferred until infection resolves and the patient is hemodynamically stable.

Source control is as important as antibiotics in complicated pyelonephritis. Antibiotics alone fail when obstruction or abscess persists.

Indications for urologic intervention:

Decompression options (in order of preference per urology):

Abscess management:

Emphysematous pyelonephritis:

Other procedural considerations:

Special Populations — Elderly and Renal/Hepatic Impairment

— Often present atypically: delirium, falls, anorexia, generalized weakness, hypothermia

— Distinguish symptomatic UTI from asymptomatic bacteriuria — up to 50% of nursing-home women have asymptomatic bacteriuria; treating it causes harm

— Localizing urinary symptoms or new systemic findings warrant treatment; isolated cloudy urine does not

— Higher rates of resistant organisms, catheter-associated infections, enterococci

— Lower physiologic reserve: more likely to require admission, develop AKI, decompensate

— Beers criteria: avoid nitrofurantoin if CrCl <30 (and remember it doesn't treat pyelo anyway); use caution with fluoroquinolones (tendinopathy, QT, delirium, aortic aneurysm risk)

— Adjust doses:

— Ciprofloxacin, levofloxacin: reduce frequency if CrCl <50

— TMP-SMX: half-dose if CrCl 15–30; avoid if <15 (hyperkalemia, worsening renal function)

— Beta-lactams: dose-adjust nearly all (cefepime neurotoxicity at high levels in CKD — myoclonus, encephalopathy)

— Aminoglycosides: extended-interval dosing with levels; avoid in severe CKD

— Vancomycin: trough or AUC-guided in CKD

— Avoid nephrotoxins (NSAIDs, contrast when possible) during AKI

— Monitor creatinine daily inpatient

— Few major adjustments for typical pyelonephritis antibiotics

— Caution with high-dose TMP-SMX (hepatotoxicity) and ceftriaxone (biliary sludging, avoid in neonates)

— Watch for drug interactions (warfarin–TMP-SMX, FQs and QT-prolonging drugs)

— Review for QT-prolonging meds before adding FQ

— Hold metformin during AKI or contrast imaging

Step 3 management: A nursing-home resident with new delirium and a positive urine culture but no fever, no leukocytosis, no urinary symptoms has asymptomatic bacteriuria — workup the delirium for other causes (medications, hypoxia, electrolytes, stroke) before attributing it to UTI; do not start antibiotics reflexively.

Elderly patients (≥65):

Renal impairment:

Hepatic impairment:

Polypharmacy:

Special Populations — Pregnancy and Pediatrics

— Pyelonephritis complicates 1–2% of pregnancies; most common in second trimester

— Risks: preterm labor, preterm birth, sepsis, ARDS, anemia, pyelonephritis recurrence

— Right-sided in ~50% (dextrorotation of gravid uterus)

— Default management: admit for IV antibiotics — Step 3 default answer

— Empiric IV ceftriaxone is the workhorse; alternatives: cefepime, aztreonam (penicillin allergy), or pip-tazo if severe

— Avoid in pregnancy: fluoroquinolones (cartilage), TMP-SMX (folate antagonist in T1, kernicterus near term), aminoglycosides (use cautiously; ototoxicity)

— Nitrofurantoin: avoid at term (≥36 weeks) due to neonatal hemolysis; doesn't treat pyelo regardless

— Continue IV until afebrile 24–48 h, then oral cephalosporin (cephalexin) to complete 10–14 days

— Suppressive nitrofurantoin or cephalexin daily until 6 weeks postpartum to prevent recurrence

— Screen and treat asymptomatic bacteriuria during pregnancy — early-pregnancy urine culture is standard

— Fetal monitoring, OB co-management, watch for preterm contractions, ARDS (fluid overload risk)

— Febrile UTI in children = pyelonephritis until proven otherwise

— Obtain catheterized or suprapubic specimen in non-toilet-trained children — bag urine is for screening only

— Empiric options: oral cephalosporin (cefixime, cefpodoxime) for well-appearing children >2 months; IV ceftriaxone if ill, vomiting, or <2 months

— Duration: 7–14 days

— Imaging (AAP guidelines): renal/bladder US after first febrile UTI in children 2–24 months; VCUG if US abnormal or recurrent febrile UTI to evaluate for vesicoureteral reflux

— Refer to pediatric urology for VUR grade III–V or recurrent infections

Board pearl: In pregnancy, always treat asymptomatic bacteriuria (3–7 day course based on organism) — it progresses to pyelonephritis in 20–40% if untreated and is the only adult outpatient indication besides pre-urologic procedures.

Pregnancy:

Pediatrics:

Complications and Adverse Outcomes

— Sepsis and septic shock: highest immediate mortality driver; activate sepsis bundle

— AKI: prerenal (sepsis, dehydration), intrinsic (acute interstitial nephritis from antibiotics), postrenal (obstruction)

— Bacteremia: 20–30% of admitted patients; doesn't necessarily prolong antibiotics if source controlled and clinically improving

— Perinephric or renal abscess: suspect when fever persists >72 hours despite appropriate antibiotics; image with CT

— Emphysematous pyelonephritis: gas-forming infection in diabetics; high mortality

— Pyonephrosis: pus in obstructed collecting system — surgical emergency

— Papillary necrosis: sloughed papilla causing obstruction; risk factors include diabetes, sickle cell, analgesic abuse, obstruction itself

— ARDS: especially in pregnant patients with pyelonephritis (capillary leak)

— Preterm labor and birth

— Maternal sepsis, ARDS, anemia

— Fetal demise (rare)

— Renal scarring — particularly in children with VUR; can lead to hypertension and CKD

— Chronic pyelonephritis: recurrent infections with permanent parenchymal damage, fibrosis, contracted kidney

— Xanthogranulomatous pyelonephritis: chronic destructive granulomatous infection, often associated with Proteus and staghorn calculi — treatment is nephrectomy

— Recurrent pyelonephritis (5–10% within 6 months)

— C. difficile colitis from broad-spectrum antibiotics

— Antibiotic-induced AKI (especially aminoglycosides, vancomycin)

— Fluoroquinolone tendinopathy, QT prolongation, aortic aneurysm/dissection, neuropathy

— Contrast-induced nephropathy

— Age >65, immunocompromise, diabetes, obstruction, delay in source control, multidrug resistance, septic shock

Key distinction: Persistent fever at 72 hours on appropriate antibiotics has three drivers to investigate: (1) abscess or obstruction (image), (2) resistant organism (review culture and susceptibilities), and (3) alternate diagnosis (reconsider — pancreatitis, cholecystitis, PID, renal vein thrombosis can mimic).

Acute complications:

Pregnancy-specific complications:

Long-term sequelae:

Iatrogenic complications:

Markers of poor prognosis:

When to Escalate Care — ICU, Consult, Transfer

— Septic shock requiring vasopressors after adequate fluid resuscitation

— Lactate ≥4 mmol/L or persistent ≥2 after resuscitation

— Respiratory failure (ARDS, especially in pregnancy)

— Altered mentation/encephalopathy attributable to sepsis

— Acute kidney injury requiring renal replacement therapy

— Multi-organ dysfunction

— Need for invasive hemodynamic monitoring

— Lactate measurement

— Blood cultures × 2 before antibiotics (if no delay)

— Broad-spectrum antibiotics within 1 hour

— 30 mL/kg crystalloid for hypotension or lactate ≥4

— Vasopressors (norepinephrine first-line) to maintain MAP ≥65 if fluid-refractory

— Reassess at 3 and 6 hours

— Urology: obstruction, abscess, emphysematous pyelo, recurrent infections, complex stones, possible nephrectomy

— Interventional radiology: percutaneous nephrostomy, abscess drainage

— Infectious diseases: MDR organisms, ESBL/CRE, treatment failures, transplant patients, complex immunocompromise

— Nephrology: AKI requiring dialysis, complex CKD management, transplant kidney

— OB: all pregnant patients, fetal monitoring, preterm labor management

— Pediatrics/pediatric urology: young children, VUR

— Facility lacking IR or urology coverage when source control needed

— Lack of ICU capability for septic shock

— Transplant recipient → transfer to transplant center

— Pregnancy with maternal-fetal medicine needs

— Use structured handoff (SBAR, I-PASS)

— Convey culture data, antibiotic timing, hemodynamic trends, pending studies

CCS pearl: When a hospitalized pyelonephritis patient drops blood pressure to 80/50 despite 2 L of fluid, the CCS sequence is second fluid bolus, repeat lactate, broaden antibiotics if not already, start norepinephrine, transfer to ICU, place arterial and central lines, repeat blood cultures, urology consult to re-evaluate for occult obstruction or abscess.

ICU admission criteria:

Sepsis bundle (Hour-1):

Specialty consultations:

Transfer considerations:

Communication and handoffs:

Key Differentials — Same-Category (Urinary) Causes

— Lower tract only: dysuria, frequency, urgency, suprapubic discomfort

— No fever, no flank pain, no systemic symptoms

— Treated with short-course nitrofurantoin, TMP-SMX, or fosfomycin (3–5 days)

— Key Step 3 trap: fever distinguishes pyelo from cystitis — don't undertreat

— Fever, dysuria, perineal/pelvic pain, tender, boggy prostate

— Treated like pyelonephritis but longer duration (4–6 weeks) to penetrate prostate

— Avoid vigorous prostate massage in acute setting (bacteremia)

— Imaging if not improving — prostatic abscess

— Recurrent UTIs in a man, same organism — think prostate as reservoir

— Fluoroquinolone 4–6 weeks; consider TMP-SMX

— Scrotal pain and swelling, fever; sexually active young men think gonorrhea/chlamydia; older men think Enterobacteriaceae

— Differentiate from testicular torsion (acute, no fever, abnormal cremasteric reflex, US Doppler)

— Colicky flank pain radiating to groin, hematuria

— Afebrile, normal UA WBC, may have hematuria only

— CT shows stone without inflammatory changes

— Becomes an emergency when infection superimposed

— Often complications of pyelonephritis, but can present de novo

— Persistent fever despite antibiotics → image

— Drainage criteria as above

— Flank pain, hematuria, proteinuria (nephrotic syndrome association)

— CT venogram diagnostic; anticoagulation

— Diabetic, sickle cell, NSAID use, obstruction; sloughed papilla in urine; classic "ring sign" on imaging

— Suprapubic pain, palpable bladder, post-void residual high

— Catheterize; rule out obstruction

Key distinction: A man with recurrent same-organism UTIs has chronic prostatitis until proven otherwise — treat with 4–6 weeks of fluoroquinolone or TMP-SMX, and counsel that prostate is a sanctuary site for bacteria.

Acute cystitis:

Acute prostatitis (men):

Chronic bacterial prostatitis:

Epididymo-orchitis:

Ureteral or renal calculi without infection:

Renal abscess and perinephric abscess:

Renal vein thrombosis:

Papillary necrosis:

Urinary retention with overflow:

Key Differentials — Other-Category Causes

— Acute appendicitis: RLQ pain, migration from periumbilical, fever; sterile pyuria possible from contiguous inflammation

— Acute cholecystitis: RUQ pain, Murphy's sign, fever, LFT changes

— Acute pancreatitis: epigastric pain radiating to back, elevated lipase

— Diverticulitis: LLQ pain, fever; CT diagnostic

— Mesenteric ischemia: "pain out of proportion to exam," elevated lactate, vasculopathy

— Hepatic or splenic abscess: fever, RUQ/LUQ pain, imaging

— PID and tubo-ovarian abscess: cervical motion tenderness, vaginal discharge, sexual history

— Ovarian torsion: acute pelvic pain, US Doppler

— Ectopic pregnancy: positive β-hCG, pelvic pain, vaginal bleeding

— Endometritis: postpartum or post-procedural fever

— Vertebral osteomyelitis or epidural abscess: back pain, fever, neurologic deficits; MRI spine if suspected — devastating if missed

— Psoas abscess: flank/back pain, fever, hip flexion deformity; CT

— Lower-lobe pneumonia: can refer to upper abdomen/flank; chest exam, CXR

— Pulmonary embolism: can mimic with pleurisy, fever, tachycardia

— Aortic dissection or AAA: back/flank pain, hemodynamic changes — fluoroquinolone history is a Step 3 trigger

— Endocarditis with renal embolic phenomena: murmur, embolic stigmata, blood cultures

— Herpes zoster: dermatomal pain preceding rash

— Adrenal hemorrhage (anticoagulated patient): flank pain, hypotension

— DKA with abdominal pain: AG metabolic acidosis; pyelonephritis can precipitate DKA — treat both simultaneously

Board pearl: Sterile pyuria (WBCs without bacteria) has its own differential: partially treated UTI, urethritis (chlamydia/gonorrhea), tuberculosis of the urinary tract, interstitial nephritis, nephrolithiasis, appendicitis adjacent to ureter, and analgesic nephropathy — workup depends on clinical context.

Intra-abdominal:

Gynecologic (women):

Musculoskeletal/spinal:

Thoracic:

Cardiovascular:

Neurologic/systemic:

Metabolic/toxic:

Secondary Prevention and Discharge Planning

— Afebrile ≥24 hours

— Hemodynamically stable

— Tolerating PO fluids and medications

— Pain controlled on oral regimen

— Source control achieved if needed

— Susceptibility-directed oral regimen identified

— Patient understands medication plan and red flags

— Oral antibiotic tailored to culture and susceptibilities; total duration calculated from start of effective therapy (typically 7 days FQ, 10–14 days beta-lactam, 14 days complicated/men)

— Analgesia (acetaminophen ± short opioid course if needed; avoid NSAIDs in AKI)

— Antiemetic PRN

— Stool softener if opioids

— Complete the full antibiotic course

— Hydrate well

— Return if: fever recurs, vomiting prevents medication, worsening pain, decreased urination, lightheadedness, confusion

— Avoid sexual activity until symptoms resolve; counsel on post-coital voiding

— Hydration (2–3 L/day)

— Post-coital voiding

— Avoid spermicides; reconsider diaphragm

— Cranberry products: weak evidence, low harm

— Topical vaginal estrogen in postmenopausal women — strong evidence for reducing recurrence

— Probiotics: limited evidence

— Continuous low-dose: nitrofurantoin 50–100 mg, TMP-SMX SS, or cephalexin 125–250 mg nightly × 6–12 months

— Post-coital prophylaxis: single dose after intercourse

— Patient-initiated self-treatment in reliable patients

— Refer to urology for recurrent pyelonephritis, men with first febrile UTI, suspected anatomic abnormality, persistent hematuria

— Imaging (US, CT) and possibly cystoscopy outpatient

Step 3 management: A postmenopausal woman with three episodes of pyelonephritis in a year deserves a urology referral, urinary tract imaging, post-void residual measurement, and a trial of vaginal estrogen — pharmacologic prophylaxis is reserved for those failing behavioral and topical measures.

Discharge readiness criteria:

Discharge medication:

Patient education (teach-back):

Secondary prevention strategies (recurrent pyelonephritis):

Prophylactic antibiotics for recurrent UTI (≥2 in 6 months or ≥3/year):

Structural workup:

Follow-Up, Monitoring, and Counseling

— 48–72 hour check (phone or visit) for all outpatient pyelonephritis — assess clinical response and review culture

— In-person visit at end of therapy if symptoms persist or complicating factors

— Reculture only if persistent symptoms, pregnancy, or recurrent infection — not routine test-of-cure

— Test-of-cure urine culture 1–2 weeks after completing therapy

— Monthly surveillance urine cultures through pregnancy

— Suppressive prophylaxis until 6 weeks postpartum if recurrence or severe initial episode

— OB follow-up for fetal surveillance

— PCP visit within 1–2 weeks

— Repeat creatinine in 1–2 weeks if AKI occurred

— Imaging follow-up for abscess: repeat CT or US in 2–4 weeks to confirm resolution

— Urology follow-up for any structural finding or recurrent disease

— Renal/bladder US after first febrile UTI in children 2–24 months

— VCUG if abnormal US or recurrent febrile UTI

— Long-term BP monitoring and urinalysis if scarring documented

— Symptom resolution within 48–72 hours

— Creatinine if AKI occurred

— Adverse drug effects: tendons, QT, GI, C. difficile

— Glucose monitoring in diabetics during illness

— Hydration and voiding habits

— Sexual health and spermicide alternatives

— Recognizing recurrence early

— Adherence to full antibiotic course; never share antibiotics

— Vaccination updates (pneumococcal, influenza in elderly, COVID)

— Diabetes control as UTI prevention

— Medication cost: generic FQs, TMP-SMX, cephalexin are inexpensive; help with access

— Coordinate with pharmacy for adherence support

— Document susceptibility data in EHR for future episodes

Board pearl: Routine test-of-cure urine culture is NOT recommended after uncomplicated pyelonephritis in non-pregnant adults — clinical resolution is sufficient; reculture is reserved for pregnancy, persistent symptoms, or recurrent disease.

Outpatient follow-up cadence:

Pregnancy-specific follow-up:

Post-hospitalization:

Pediatric follow-up:

Monitoring parameters during/after treatment:

Counseling priorities:

Health systems considerations:

Ethical, Legal, and Patient Safety Considerations

— Inappropriate antibiotic use drives resistance, C. difficile infection, AKI, and adverse drug events

— Reflex treatment of asymptomatic bacteriuria in elderly and patients with catheters is a major stewardship failure — Choosing Wisely target

— De-escalate based on cultures; document rationale

— Discuss antibiotic risks, particularly fluoroquinolones: FDA black-box warnings for tendinopathy/rupture, QT prolongation, peripheral neuropathy, CNS effects, aortic aneurysm/dissection, hypoglycemia — reserve for cases without safer alternatives, especially in elderly

— For procedures (nephrostomy, drainage, nephrectomy): consent must include risks of bleeding, infection, injury to adjacent structures, possible need for further procedures

— Discharge handoffs must communicate pending cultures, sensitivity results, antibiotic duration, follow-up plan, and red-flag return precautions

— Pending culture results at discharge are a major safety gap — many institutions have automated callback systems; ensure follow-up

— Medication reconciliation: drug interactions (warfarin–TMP-SMX, FQ–warfarin, FQ–antacids/cations reducing absorption)

— STIs identified during workup (gonorrhea, chlamydia) are reportable

— Multidrug-resistant organisms (CRE, ESBL) may have local reporting requirements

— TB in genitourinary system: reportable

— Septic patients may have altered capacity; surrogate decision-making for procedures; document carefully

— Pregnant patients have autonomy regarding hospitalization; counsel on maternal and fetal risks of refusal

— Outpatient treatment requires reliable transportation, follow-up access, and ability to afford medications — assess social determinants before discharge

— Language barriers: use certified interpreters for counseling and consent

— Severity assessment, disposition rationale, culture/susceptibility review, follow-up arrangements

Step 3 management: A patient discharged on empiric ciprofloxacin whose culture later returns resistant E. coli requires proactive callback, change to a susceptible agent, and documentation of the conversation — failure to follow up on pending results is a sentinel patient safety event and a frequent malpractice trigger.

Antibiotic stewardship as patient safety:

Informed consent considerations:

Transitions of care risks (high-yield Step 3 patient safety domain):

Mandatory reporting and public health:

Capacity and refusal:

Equity and access:

Documentation pearls:

High-Yield Associations and Rapid-Fire Facts

— E. coli: dominant in all settings (75–90%)

— Proteus mirabilis: urease-producing → struvite stones, alkaline urine, staghorn calculi

— Klebsiella pneumoniae: diabetics, emphysematous pyelonephritis

— Pseudomonas: healthcare-associated, catheterized, post-instrumentation

— Staphylococcus saprophyticus: young sexually active women

— Staphylococcus aureus: hematogenous spread; think endocarditis or bacteremia source

— Candida: immunocompromised, diabetics, catheters; often colonization not infection

— Enterococcus: elderly, catheters, prior cephalosporin exposure

— Striated nephrogram on CT — pyelonephritis

— Gas in renal parenchyma — emphysematous pyelonephritis

— Staghorn calculus — Proteus, struvite

— Bear paw sign on imaging — xanthogranulomatous pyelonephritis

— "Bunch of grapes" hydronephrosis in pediatric VUR

— Nitrofurantoin and fosfomycin: don't work for pyelo — inadequate tissue levels

— Fluoroquinolones: chelate with calcium, antacids, iron — separate dosing by 2–6 hours

— TMP-SMX: warfarin interaction (INR rise), hyperkalemia, sulfa allergy

— Ceftriaxone: avoid in neonates and with calcium-containing IV fluids

— Aminoglycosides: nephrotoxic, ototoxic; once-daily extended-interval dosing

Board pearl: Alkaline urine with struvite crystals and a staghorn calculus = Proteus mirabilis infection — these stones require complete surgical removal (PCNL) because residual fragments perpetuate infection.

Microbiology associations:

Imaging signs:

Pharmacology pearls:

Pregnancy: treat asymptomatic bacteriuria; admit pyelonephritis; avoid FQ, TMP-SMX (T1, T3), aminoglycosides if alternatives

Diabetics: higher risk of emphysematous pyelo, abscess, candida, papillary necrosis; control glucose aggressively during infection

Sickle cell: papillary necrosis and increased UTI risk

Transplant kidney: lower threshold for admission and imaging; ID and transplant team consultation

Recurrent pyelonephritis in men or children: structural workup mandatory

USPSTF: screen for asymptomatic bacteriuria in pregnancy (grade A); do not screen in non-pregnant adults (grade D)

Quality measure: sepsis bundle compliance (SEP-1) — antibiotics within 1 hour, lactate, cultures, fluids

Board Question Stem Patterns

Step 3 management: When the stem mentions persistent fever beyond 72 hours of appropriate therapy, the next best step is almost always CT abdomen/pelvis with contrast to evaluate for abscess or obstruction — image before changing antibiotics blindly.

Stem 1 — Outpatient candidate: A 28-year-old healthy woman with 2 days of fever, flank pain, dysuria, T 38.6°C, HR 96, BP 118/72, tolerating fluids, urinalysis with pyuria and bacteriuria. → Outpatient oral fluoroquinolone after a single IV/IM dose of ceftriaxone, with 48-hour follow-up

Stem 2 — Pregnancy: 24-year-old at 22 weeks with fever, R flank pain, vomiting. → Admit, IV ceftriaxone, fetal monitoring, transition to oral cephalexin to complete 14 days, suppression until postpartum

Stem 3 — Septic shock with obstruction: 65-year-old diabetic with fever, hypotension, hydronephrosis and ureteral stone on CT. → Sepsis bundle within 1 hour, ICU, urology consult for percutaneous nephrostomy, broad-spectrum antibiotics (pip-tazo)

Stem 4 — Emphysematous pyelonephritis: Poorly controlled diabetic not improving on antibiotics at 72 hours; CT shows gas in renal parenchyma. → Urology consult, percutaneous drainage, broad-spectrum antibiotics; nephrectomy if extensive or failed drainage

Stem 5 — Treatment failure: Patient on ciprofloxacin for 3 days with persistent fever; culture pending. → CT abdomen/pelvis to evaluate for abscess or obstruction, broaden antibiotics, review culture

Stem 6 — Asymptomatic bacteriuria: Nursing-home resident with positive urine culture, no symptoms, no fever. → Do NOT treat — investigate other delirium causes if present

Stem 7 — Recurrent UTI in a man: 45-year-old man with three UTIs in 6 months, same organism. → Chronic bacterial prostatitis; 4–6 weeks of fluoroquinolone, urology referral

Stem 8 — Pediatric febrile UTI: 9-month-old with fever, irritability, positive catheterized urine. → IV ceftriaxone, admit if ill, renal US after, VCUG if abnormal or recurrent

Stem 9 — Resistance: Patient with pyelonephritis, recent FQ exposure 2 months ago. → Don't repeat FQ empirically; use ceftriaxone or carbapenem pending cultures

Stem 10 — Sterile pyuria: Symptoms with WBCs but no bacteria. → Workup: chlamydia/gonorrhea NAAT, TB, partially treated UTI, interstitial nephritis

Stem 11 — Discharge red flag: Patient sent home but culture later resistant. → Callback, change antibiotic, document

One-Line Recap

Pyelonephritis management hinges on a clean triage decision between outpatient oral therapy in stable, non-pregnant, PO-tolerant patients with reliable follow-up and inpatient IV therapy for sepsis, pregnancy, obstruction, immunocompromise, or treatment failure — with antibiotic choice guided by local resistance, source control prioritized when complications arise, and stewardship discipline applied throughout.

Board pearl: The two most common Step 3 traps in pyelonephritis are (1) using nitrofurantoin or fosfomycin (inadequate renal tissue penetration — wrong drug class) and (2) treating asymptomatic bacteriuria outside of pregnancy and pre-urologic procedures (drives resistance and C. difficile) — avoid both and you will outperform most test takers on this topic.

Triage trumps all: Hemodynamics, PO tolerance, pregnancy, comorbidity, and follow-up reliability decide outpatient versus inpatient — not the urinalysis alone.

Empiric antibiotics: Outpatient = ciprofloxacin 7 days (if resistance <10%) or single ceftriaxone dose then oral step-down; Inpatient = IV ceftriaxone; severe sepsis or healthcare exposure = pip-tazo or carbapenem; always tailor to culture in 48–72 hours.

Pregnancy is its own algorithm: Admit, IV beta-lactam, avoid FQ/TMP-SMX/aminoglycosides when possible, 14-day total course, suppressive therapy until 6 weeks postpartum, always treat asymptomatic bacteriuria.

Persistent fever at 72 hours = image: CT abdomen/pelvis to find abscess, obstruction, or emphysematous pyelonephritis; source control (nephrostomy, drainage, occasionally nephrectomy) is as important as antibiotics in complicated disease.